Scott Robertson

Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar.

Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar.

Finistere Ventures LLC (Finistere Ventures) is a venture capital firm founded by Spencer Maughan and Arama Kukutai in 2005. The firm is headquartered in Newport Beach, California.

Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar.

Finistere Ventures LLC (Finistere Ventures) is a venture capital firm founded by Spencer Maughan and Arama Kukutai in 2005. The firm is headquartered in Newport Beach, California.

Finistere Ventures LLC (Finistere Ventures) is a venture capital firm founded by Spencer Maughan and Arama Kukutai in 2005. The firm is headquartered in Newport Beach, California.

Finistere Ventures LLC (Finistere Ventures) is a venture capital firm founded by Spencer Maughan and Arama Kukutai in 2005. The firm is headquartered in Newport Beach, California.

Finistere Ventures LLC (Finistere Ventures) is a venture capital firm founded by Spencer Maughan and Arama Kukutai in 2005. The firm is headquartered in Newport Beach, California.

Finistere Ventures LLC (Finistere Ventures) is a venture capital firm founded by Spencer Maughan and Arama Kukutai in 2005. The firm is headquartered in Newport Beach, California.

Finistere Ventures LLC (Finistere Ventures) is a venture capital firm founded by Spencer Maughan and Arama Kukutai in 2005. The firm is headquartered in Newport Beach, California.

Finistere Ventures LLC (Finistere Ventures) is a venture capital firm founded by Spencer Maughan and Arama Kukutai in 2005. The firm is headquartered in Newport Beach, California.

Finistere Ventures LLC (Finistere Ventures) is a venture capital firm founded by Spencer Maughan and Arama Kukutai in 2005. The firm is headquartered in Newport Beach, California.

Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar.

Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar.